Association of vasculitic glomerulonephritis with membranous nephropathy: a report of 10 cases

Tse, W. Y.; Howie, Alexander J.; Adu, D.; Savage, C. O. S.; Richards, Nicholas T.; Wheeler, David C.; Michael, J.

doi:10.1093/ndt/12.5.1017

Cited by 64 publications

(51 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Unlike MN, which often has an insidious course progressing to renal failure over many years, patients with superimposed crescentic GN generally have a more aggressive clinical course and may present with or progress rapidly to renal failure [10,11]. These patients may present with a rapidly progressive glomerulonephritis or develop a nephritic picture after initially presenting with a nephrotic syndrome.…”

Section: Discussionmentioning

confidence: 99%

“…Coexistent MN and PNCGN is a rare occurrence, with only 25 reported cases in the English literature in which clinical and pathologic findings are detailed [9,[12][13][14][15][16][17][18]. Thirteen patients had P-ANCA by indirect immune fluorescent (IIF) staining, seven of whom were tested with ELISA and found to have MPO-ANCA.…”

Section: Discussionmentioning

confidence: 99%

“…Patients with both MN and PNCGN are likely to have heavier proteinuria than patients with PNCGN alone. All of 25 reported cases with urine output had proteinuria [9,[12][13][14][15][16][17][18]. From the recent report, the mean 24-h urine protein for these patients was 6.5 g, compared with 1.7 to 2.5 g in patients with ANCA disease alone [22].…”

Section: Discussionmentioning

confidence: 99%

“…Although the treatment of MN is often supportive, renal vasculitis characteristically responds well to treatment with cyclophosphamide (CY) and prednisone [11]. Among the 25 reported cases of MN and PNCGN, induction therapy consisted of prednisone and CY in 20 patients, prednisone and azathioprine in one patient, and prednisone alone in one patient.…”

Section: Discussionmentioning

confidence: 99%

“…Among the 25 reported cases of MN and PNCGN, induction therapy consisted of prednisone and CY in 20 patients, prednisone and azathioprine in one patient, and prednisone alone in one patient. One patient received mycophenolate mofetil and two patients also received plasmapheresis [9,[12][13][14][15][16][17][18].…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

Coexistent Membranous Nephropathy with Doubly ANCA-Associated Crescentic Glomerulonephritis: A Case Report and Review of Literature

Chanprasert¹,

Cheungpasitporn²,

Eldred³

2011

J Nephrol Therapeutic

View full text Add to dashboard Cite

Introduction: Membranous nephropathy (MN) is the most common causes of the nephrotic syndrome in nondiabetic, Caucasian adults. Pauci-immune necrotizing and crescentic glomerulonephritis (PNCGN) typically present with rapidly progressive glomerulonephritis. Coexistent MN and PNCGN is a rare occurrence. We report a case of both MPO-and PR3-ANCA associated NCGN with MN that presented as rapidly progressive glomerulonephritis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Coexistent Membranous Nephropathy with Doubly ANCA-Associated Crescentic Glomerulonephritis: A Case Report and Review of Literature

Chanprasert¹,

Cheungpasitporn²,

Eldred³

2011

J Nephrol Therapeutic

View full text Add to dashboard Cite

show abstract

NK026680, a novel suppressant of dendritic cell function, prevents the development of rapidly progressive glomerulonephritis and perinuclear antineutrophil cytoplasmic antibody in SCG/Kj mice

Saiga¹,

Tokunaka²,

Ichimura³

et al. 2006

Arthritis & Rheumatism

View full text Add to dashboard Cite

Objective. NK026680 is a newly identified type of immunosuppressive agent that inhibits dendritic cell (DC) functions and consequently reduces the mortality of mice with experimental acute graft-versus-host disease. This study was undertaken to evaluate NK026680 suppression of DC functions in preventing development of rapidly progressive glomerulonephritis (RPGN) and perinuclear antineutrophil cytoplasmic antibodies (pANCA) in SCG/Kj mice.Methods. Oral administration of NK026680 to SCG/Kj mice began when mice were 8-10 weeks old, before the onset of disease, and continued for 56 days. The efficacy of NK026680 was evaluated using the mortality of mice, the results of urinalysis, histopathologic evaluation for glomerular injury, and immunofluorescence staining for the detection of immune complex (IC) deposition in glomeruli, and by assessing lymphadenopathy and measuring autoantibody titers.Results. Oral administration of NK026680 at a dosage of 25 mg/kg once daily or 50 mg/kg once daily significantly suppressed 1) spontaneous mortality, 2) proteinuria and hematuria, 3) blood urea nitrogen levels, 4) glomerular damage characterized histopathologically, 5) IC deposition in glomeruli, 6) the development of pANCA and anti-DNA antibodies, and 7) lymphadenopathy. Conclusion. The newly identified DC inhibitor, NK026680, prevented the onset of RPGN, autoantibody production, and lymphadenopathy in SCG/Kj mice, suggesting a crucial role for DC function in these autoimmune phenotypes. NK026680 may be a potent immunosuppressive agent for the treatment of ANCAassociated renovascular disorders.Dendritic cells (DCs) play a central role in initiating and regulating immune responses through antigen presentation (signal 1), costimulatory signals (signal 2), and soluble factors (1,2). Several studies have demonstrated that blockade of the costimulatory signal from DCs markedly suppresses autoimmune diseases (3) and, conversely, that the prolonged presentation of self antigens by DCs exacerbates autoimmune diseases in animal models (4-7). These findings confirm the pathologic role of DCs in the pathogenesis of autoimmune diseases, suggesting that DC function is a potential target for autoimmune therapy. We therefore attempted to develop a pharmacologic approach to suppressing DC functions in vivo.Recently, we succeeded in isolating a new type of immunosuppressive agent, NK026680, by screening a large number of synthetic compounds.

show abstract

Membranous glomerulopathy

Short¹

The Treatment of Glomerulonephritis

View full text Add to dashboard Cite

Association of vasculitic glomerulonephritis with membranous nephropathy: a report of 10 cases

Cited by 64 publications

References 4 publications

Coexistent Membranous Nephropathy with Doubly ANCA-Associated Crescentic Glomerulonephritis: A Case Report and Review of Literature

Coexistent Membranous Nephropathy with Doubly ANCA-Associated Crescentic Glomerulonephritis: A Case Report and Review of Literature

NK026680, a novel suppressant of dendritic cell function, prevents the development of rapidly progressive glomerulonephritis and perinuclear antineutrophil cytoplasmic antibody in SCG/Kj mice

Membranous glomerulopathy

Contact Info

Product

Resources

About